FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis

FDA approves Sanofi and Regeneron’s Dupixent to treat prurigo nodularis

Source: 
Pharmaceutical Business Review
snippet: 

This approval makes Dupixent the first and only medicine available in the US for the treatment of prurigo nodularis, a chronic and debilitating skin disease.